Developing a small molecule API is often a perilous process for new and emerging pharma companies. The primary goal, whether in early- or late-phase development, is to obtain sufficient material to support your clinical requirements. Yet the regulatory requirements for each phase are different, and they require different skill sets. Here, three of our leading API experts discuss these key challenges, what your company needs to succeed, and how partnering with a capable CDMO can make the biggest difference of all.
- Stephen Boppart, Director Business Management, API
- Matt Frizzle, Senior Business Manager, API
- Iain McGroarty, Senior Business Development Executive, API